NewsSource: EClinCloud

Invitation | March 7–8 in Chengdu: EClinCloud Invites You to the 7th Chengdu Biopharmaceutical Innovators Summit

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

March 7–8
The 7th Chengdu Biopharmaceutical Innovators Summit will be held
Dr. Qin Long, Founder & CEO of EClinCloud, will
appear at the March 7 "Patient-Centric Clinical Trials Subforum"
to present "Enabling Patient-Centric Clinical Trials with eCOA"
We sincerely welcome your attendance!
Article illustration

Dates: March 7–8, 2024

Venue: Chengdu Zhengyuan Xiyue Hotel, Floors 3–4

Organizer: Yaorongquan (药融圈)

Supporting Organizations: Chengdu Biomedical Information Society; High-Tech Zone Experts Association; China Pharmaceutical University Sichuan Alumni Association; Tianfu Life Science Park; Linyanren Platform

The NDC x 2024 New Drug Innovators Summit will be held on March 7–8, 2024, in Chengdu. The conference will cover cutting-edge developments in ADC, modified new drug, small-molecule new drug, and GLP-1 drug R&D, with a focus on the latest clinical progress, aiming to break down industry information barriers and drive diverse innovation.
Article illustration

*Registration is free for a limited time

Register now to reserve your seat

Conference Framework

Article illustration

Conference Agenda



Conference Agenda Featuring Dr. Qin Long's Presentation

Article illustration

Article illustration


The full conference agenda is as follows (the schedule is subject to change; please refer to the on-site schedule):


March 7




Article illustration
Article illustration
Article illustration
Article illustration
Article illustration
Article illustration
Article illustration


Article illustration


March 8


Article illustration
Article illustration


Article illustration
Article illustration
Article illustration



*Registration is free for a limited time

Register now to reserve your seat




About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interconnected all-in-one clinical trial cloud platform (covering eCOA, CTMS, eTMF, EDC, RTSM, RM , and other technology products and solutions, with capabilities such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis), as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining cutting-edge technology with life data, EClinCloud builds a globally leading "patient-centric" SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.







Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.